This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Silence Therapeutics plc is a biotechnology company focused on discovering and developing novel therapeutics using its proprietary siRNA technology. The company’s preclinical research and development pipeline necessitates animal testing to comply with regulatory requirements for drug safety and efficacy. A 2022 preclinical toxicology study for its candidate SLN360 explicitly details animal studies performed in compliance with animal welfare standards. This reliance on animal models for biomedical analysis places the company on the Cruelty Free Investors exclusion list for animal exploitation. As a clinical-stage biopharmaceutical firm, animal testing is central to its core business of bringing new drugs to market.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.